第一三共におけるCOVID-19 ワクチン開発への取り組み
Development of COVID-19 vaccine in Daiichi Sankyo

丹澤 亨, 藤谷 純章, 籔田 雅之
Toru Tanzawa, Sumiaki Fujitani, Masayuki Yabuta

日本知財学会誌Vol.20 No.1 p.43-49 (2023-9-20)
Journal of Intellectual Property Association of Japan Vol.20 No.1 p.43-49 (2023-9-20)

＜要旨＞
2019年12月に中国湖北省武漢市に端を発した新型コロナウイルス感染症（COVID-19）は急激な勢いで拡大し，全世界の社会・経済に深刻な影響を与えた．その中でこれまでにないスピードで診断薬，治療薬やワクチンの開発が行われ，感染拡大の防止が進められた．弊社も2020年2月より国産mRNAワクチンの開発に取り組み，2023年1月に武漢株に対する追加接種用ワクチンの承認申請を実施した．弊社のmRNAワクチン開発とその過程において経験した事柄・課題について記述する．
<Abstract>
The novel coronavirus disease（COVID-19）, which originated in Wuhan City, China in December 2019, has spread rapidly and has had a serious impact on societies and economies around the world.　Under these circumstances, diagnostic agents, therapeutic agents and vaccines were developed at an unprecedented speed, and the prevention of the spread of infection was promoted.
Daiichi Sankyo Co., Ltd. has also been working on the development of a domestic mRNA vaccine since February 2020, and in January 2023, we applied for approval for a booster vaccination against the Wuhan strain.
The challenges experienced in our mRNA vaccine development are outlined.

＜キーワード＞
COVID-19, ワクチン開発, LNP-mRNA
<Keywords>
COVID-19, Vaccine development, LNP-mRNA